+86 21 5428 1913
Welcome to Micro&Nano
Make mRNA therapy development easier!
INano™ Platform GenNano™ Platform CRO/CDMO |
We cooperate with our partners to providehigh quality and complete process CRO & CDMO services for our customers
The company not only provides a full range of RNA-LNP encapsulation equipment (including mRNA, siRNA, CRISPR/Cas9, SAMRNA, CircRNA, etc.) from the laboratory to industrialization, but also offers overall solutions.
Overall solutions focused on nanomedicine
Numerous users have obtained over 13 IND clinical trial approvals through the use of the INano platform in China, the United States, Brazil, Australia and other countries.
mRNA技术为治疗乙肝带来了希望。 2024年2月3日，我国科研团队在自然期刊发布了一项研究成果，展示了一款基于mRNA技术的慢性乙肝（CHB）疫苗。慢性乙肝是肝纤维化、肝硬化和肝癌的主要原因之一，对公共健康构成重大威胁，目前的慢性乙型肝炎治疗，主要是依靠基于核苷类药物和干扰素-α治疗，但都无法实现足够的病毒清除。 治疗性乙肝疫苗已有过多次实践，包括基于重组蛋...
5月2日， 第三届LNP制剂与工艺开发峰会在美国波士顿海港区威斯汀会展中心圆满落幕。 此次峰会提供了四个平行议题，辉瑞（Pfizer）、Moderna 和 Alnylam 等行业巨头与 Capstan Therapeutics、艾伯维（AbbVie）、Mana Bio、Serina Therapeutics、Karma Biotechnologies 等公司齐聚一堂，400 ...
脂质纳米粒-自复制RNA疫苗储存条件优化1、 简介RNA分子递送实验可以追溯到1978年，当时用脂质体将编码兔球蛋白的mRNA体外转染给小鼠淋巴细胞。从那时起，可离子化的脂质和RNA递送技术的进步导致美国食品和药物管理局（FDA）在2018年批准了**个基于siRNA的脂质纳米粒子（LNP）疗法，Onpattro(Patisiran)。到2020年初COVID-19大流行发生时，几个包裹mR...
胰腺癌(PAC)是最致命的恶性肿瘤之一，总体5年的生存率不到10%。2020年，全球报告了495,773例新的PAC病例和466,003例死亡。目前，PAC的标准治疗方法是手术切除，然后辅以吉西他滨或卡培他滨进行化疗。不幸的是，由于缺乏早期症状，大约80%-90%的PAC患者被诊断为晚期，失去了手术切除的机会。对于这些患者，通常使用化疗药物(如吉西他滨和卡培他滨)来提高他们的存活率。
据报道，2019年新型冠状病毒(COVID-19)已造成超过575万人死亡，3.9655亿人感染，包括由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)的至少五个变种引起。这种情况引起了公众对先前接种疫苗人群使用不同疫苗的增强剂能否对新的变种产生有效的免疫应答反应的担忧。我们的研究以先接种两剂灭活疫苗和间隔6个月后接种mRNA疫苗加强免疫的为基础，调查了异种疫苗接种的免疫效果。
Kdm6a (也称为UTX)基因编码组蛋白去甲基酶，称为赖氨酸特异性去甲基酶6A(KDM6A)，它是一种重要的表观遗传调节因子。KDM6A作为肿瘤抑制因子在膀胱癌(BCA)中的作用已被广泛认识。由于KDM6A的缺失会增加BCA的风险和突变，KDM6A的表达降低不仅可以预测BCA患者的不良预后，还可能表明KDM6A在BCA的肿瘤发生中发挥关键作用。
MERRYCHRISTMAS!MARRY CHRISTMASWISHWISHSanta drives an elk,The vehicle is laden with blessings, delivering an abundance of well-being and happiness.The snow in the sky gives me a night of starlight,...
祝贺健新原力赋能RNAimmune公司RSV mRNA疫苗的临床试验IND获得FDA批准！我们迈安纳的平台会持续赋能各位合作伙伴，为各位保驾护航
随着SARS-CoV-2 mRNA-LNP疫苗的成功，mRNA 脂质纳米颗粒(LNPs)被推入核酸疗法的中心舞台 。mRNA疫苗的优势在于平台的模块化和快速大生产能力。。然而，设计优化mRNA-LNP疫苗时，需要平衡其有效性、稳定性和毒性，这时往往有多种选择。本文就最关键的考察因素提供了建议
Public Health and Medical Professionals for Transparency是一家非营利性组织，由公共卫生专家、医学专家、科学家和新闻工作者组成，旨在通过获取和传播FDA批准COVID-19疫苗所依据的数据。（获取的任何数据将会公布在组织网站上。https://phmpt-org.translate.goog/?_x_tr_sl=en&_x_tr_tl=z...
Micro&Nano Biologics Co.,Ltd., founded in 2018, focusing on providing integrated mRNA delivery solutions to the sore points of RNA industry.
ABOUT US
Shang Hai
Make mRNA therapy development easier!
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clients
ADVANTAGE
Experience
Technology
Quality
Service
Micro&Nano has provided standard and customized nucleic acid drug delivery equipment and solutions to hundreds of companies and research institutions, with carrier types including LNP, polymer core-shell, PLGA, peptides, liposomes, nanocrystals, and other various types.
Micro&Nano is committed to developing customized nucleic acid drug delivery solutions using its leading proprietary Genmix™ technology. Customized equipment and solutions are developed based on customer needs and different carrier characteristics to meet the requirements of research and GMP production.
Micro&Nano's solutions can effectively control the size of nanoparticles, increase encapsulation efficiency, and have good repeatability in the preparation process, with low PDI values for product performance between batches and groups. This simplifies the overall experimental process and improves the preparation process, which can be linearly amplified through our unique Genmix™ technology.
Micro&Nano always prioritizes product and service quality, and has an experienced engineering team, GMP consulting team, and technical application team. A single batch
production line can reach over 100 liters, which helps in the conversion of nanomedicine from early-stage research to clinical products and commercial production.
Micro&Nano Biologics Co.,Ltd.
Call：+86 2154281913
Mail：info@micronanobiologics.com
Add：Building A, No. 128 Shenfu Road, Minhang District, Shanghai，China
|
|
